Exploring a Non-ATP pocket for potential allosteric modulation of pi3kα

Journal of Physical Chemistry B

Volumn 119, Issue 3, 2015, Pages 1002-1016

  Gkeka, Paraskevi ^a   Papafotika, Alexandra ^b,c   Christoforidis, Savvas ^b,c   Cournia, Zoe ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b Institute of Molecular Biology and Biotechnology Department of Biomedical Research Foundation for Research and Technology (IMBB BR FORTH)   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR DYNAMICS; PRINCIPAL COMPONENT ANALYSIS; PROTEINS;

ALLOSTERIC EFFECT; ALLOSTERIC MODULATION; ALLOSTERIC MODULATORS; ATP-BINDING SITE; KINASE INHIBITION; MOLECULAR DYNAMICS SIMULATIONS; PHOSPHOINOSITIDE 3-KINASE; SITE IDENTIFICATION;

BINDING SITES;

ADENOSINE TRIPHOSPHATE; ANILINE DERIVATIVE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIK-108; PIK3CA PROTEIN, HUMAN;

ALLOSTERISM; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYME STABILITY; GENETICS; HUMAN; METABOLISM; MOLECULAR DYNAMICS; MOUSE; MUTATION;

ADENOSINE TRIPHOSPHATE; ALLOSTERIC REGULATION; ANILINE COMPOUNDS; ANIMALS; CATALYTIC DOMAIN; CHROMONES; ENZYME INHIBITORS; ENZYME STABILITY; HUMANS; MICE; MOLECULAR DYNAMICS SIMULATION; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84921511844     PISSN: 15206106     EISSN: 15205207     Source Type: Journal    
DOI: 10.1021/jp506423e     Document Type: Article

References (62)

1. Fruman, D. A.; Meyers, R. E.; Cantley, L. C. Phosphoinositide kinases Annu. Rev. Biochem. 1998, 67, 481-507
2. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat. Rev. Cancer 2002, 2, 489-501
3. Cantley, L. C. The phosphoinositide 3-kinase pathway Science 2002, 296, 1655-1657
4. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat. Rev. Cancer 2009, 9, 550-562
5. Courtney, K. D.; Corcoran, R. B.; Engelman, J. A. The PI3K pathway as drug target in human cancer J. Clin. Oncol. 2010, 28, 1075-1083
6. Knight, Z. A.; Gonzalez, B.; Feldman, M. E.; Zunder, E. R.; Goldenberg, D. D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W. A.; Williams, R. L.; Shokat, K. M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling Cell 2006, 125, 733-747
7. Simard, J. R.; Kluter, S.; Grutter, C.; Getlik, M.; Rabiller, M.; Rode, H. B.; Rauh, D. A new screening assay for allosteric inhibitors of cSrc Nat. Chem. Biol. 2009, 5, 394-396
8. Lindsley, C. W. 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: Drug Discovery Targeting Allosteric Sites. J. Med. Chem. 2014.
9. Changeux, J. P. The concept of allosteric modulation: an overview. Drug discovery today Technologies 2013, 10, e223-228
10. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers Science 2004, 304, 554
11. Samuels, Y.; Diaz, L. A., Jr.; Schmidt-Kittler, O.; Cummins, J. M.; Delong, L.; Cheong, I.; Rago, C.; Huso, D. L.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells Cancer Cell 2005, 7, 561-573
12. Saal, L. H.; Holm, K.; Maurer, M.; Memeo, L.; Su, T.; Wang, X.; Yu, J. S.; Malmstrom, P. O.; Mansukhani, M.; Enoksson, J.; Hibshoosh, H.; Borg, A.; Parsons, R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma Cancer Res. 2005, 65, 2554-2559
13. Brana, I.; Siu, L. L. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment BMC Med. 2012, 10, 161
14. Liu, S.; Knapp, S.; Ahmed, A. A. The structural basis of PI3K cancer mutations: from mechanism to therapy Cancer Res. 2014, 74, 641-646
15. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer Nat. Rev. Drug Discovery 2009, 8, 627-644
16. Loibl, S.; von Minckwitz, G.; Schneeweiss, A.; Paepke, S.; Lehmann, A.; Rezai, M.; Zahm, D. M.; Sinn, P.; Khandan, F.; Eidtmann, H. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J. Clin. Oncol. 2014.
17. Mandelker, D.; Gabelli, S. B.; Schmidt-Kittler, O.; Zhu, J.; Cheong, I.; Huang, C. H.; Kinzler, K. W.; Vogelstein, B.; Amzel, L. M. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 16996-7001
18. Huang, C. H.; Mandelker, D.; Schmidt-Kittler, O.; Samuels, Y.; Velculescu, V. E.; Kinzler, K. W.; Vogelstein, B.; Gabelli, S. B.; Amzel, L. M. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations Science 2007, 318, 1744-1748
19. Zhang, X.; Vadas, O.; Perisic, O.; Anderson, K. E.; Clark, J.; Hawkins, P. T.; Stephens, L. R.; Williams, R. L. Structure of lipid kinase p110beta/p85beta elucidates an unusual SH2-domain-mediated inhibitory mechanism Mol. Cell 2011, 41, 567-578
20. Hon, W.-C.; Berndt, A.; Williams, R. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases Oncogene 2012, 31, 3655-3666
21. Zhao, Y.; Zhang, X.; Chen, Y.; Lu, S.; Peng, Y.; Wang, X.; Guo, C.; Zhou, A.; Zhang, J.; Luo, Y.; Shen, Q.; Ding, J.; Meng, L. Crystal structures of PI3Kalpha complexed with PI103 and its derivatives: new directions for inhibitors design ACS Med. Chem. Lett. 2014, 5, 138-142
22. Wells, G. J. Allosteric modulators of G protein-coupled receptors Curr. Top. Med. Chem. 2014, 14, 1735-7
23. Nussinov, R.; Tsai, C. J. The design of covalent allosteric drugs. Annu. Rev. Pharmacol. Toxicol. 2014.
24. Nussinov, R.; Tsai, C. J. The different ways through which specificity works in orthosteric and allosteric drugs Curr. Pharm. Des. 2012, 18, 1311-1316
25. Herbert, C.; Schieborr, U.; Saxena, K.; Juraszek, J.; De Smet, F.; Alcouffe, C.; Bianciotto, M.; Saladino, G.; Sibrac, D.; Kudlinzki, D. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling Cancer Cell 2013, 23, 489-501
26. Conn, P. J.; Lindsley, C. W.; Meiler, J.; Niswender, C. M. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders Nat. Rev. Drug Discovery 2014, 13, 692-708
27. Zhang, J.; Adrin, F. J.; Jahnke, W.; Cowan-Jacob, S. W.; Li, A. G.; Iacob, R. E.; Sim, T.; Powers, J.; Dierks, C. Targeting Bcr-Abl by combining allosteric with ATP -binding-site inhibitors Nature 2010, 463, 501-506
28. Kruse, A. C.; Ring, A. M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hubner, H.; Pardon, E.; Valant, C.; Sexton, P. M. Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 2013, 504, 101-6
29. Changeux, J. P. 50 years of allosteric interactions: the twists and turns of the models Nat. Rev. Mol. Cell Biol. 2013, 14, 819-829
30. Jorgensen, W. L. The many roles of computation in drug discovery Science 2004, 303, 1813-1818
31. Jorgensen, W. L. Efficient drug lead discovery and optimization Acc. Chem. Res. 2009, 42, 724-733
32. Lamb, M. L.; Jorgensen, W. L. Computational approaches to molecular recognition Curr. Opin. Chem. Biol. 1997, 1, 449-457
33. Sali, A.; Blundell, T. Comparative protein modelling by satisfaction of spatial restraints J. Mol. Biol. 1993, 234, 779-815
34. Ngan, C. H.; Bohnuud, T.; Mottarella, S. E.; Beglov, D.; Villar, E. A.; Hall, D. R.; Kozakov, D.; Vajda, S. FTMAP: extended protein mapping with user-selected probe molecules Nucleic Acids Res. 2012, 40, W271-W275
35. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera - a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612
36. Hess, B.; Carsten, K.; David, v. d. S.; Erik, L. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation J. Chem. Theory Comput. 2008, 4, 435-447
37. Lindorff-Larsen, K.; Piana, S.; Palmo, K.; Maragakis, P.; Klepeis, J. L.; Dror, R. O.; Shaw, D. E. Improved side-chain torsion potentials for the Amber ff99SB protein force field Proteins 2010, 78, 1950-1958
38. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of Simple Potential Functions for Simulating Liquid Water J. Chem. Phys. 1983, 79, 926-935
39. Sousa da Silva, A. W.; Vranken, W. F. ACPYPE-AnteChamber PYthon Parser interfacE BMC Res. Notes 2012, 5, 367
40. Wang, J.; Wang, W.; Kollman, P. A.; Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations J. Mol. Graphics Modell. 2006, 25, 247-260
41. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25, 1157-1174
42. Essmann, U.; Perera, L.; ML, B.; Darden, T.; Lee, M.; Pedersen, L. A smooth particle mesh Ewald method J. Chem. Phys. 1995, 103, 8577-8593
43. Nose, S. A molecular dynamics method for simulations in the canonical ensemble Mol. Phys. 1984, 255-268
44. Parrinello, M.; Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics method J. Appl. Phys. 1981, 52, 7182-7190
45. Hess, B.; Bekker, H.; Berendsen, H. J. C.; Fraaije, J. G. E. M. LINCS: A linear constraint solver for molecular simulations J. Comput. Chem. 1997, 18, 1463-1472
46. Humphrey, W.; Dalke, A.; Schulten, K. VMD: visual molecular dynamics J. Mol. Graphics 1996, 14, 33-38
47. GRaphing, Advanced Computation and Exploration (GRACE) program; Grace Development Core Team: 2011.
48. MATLAB 8.0 and Statistics Toolbox 8.1; The MathWorks, Inc: Natick, MA, 2013.
49. Daura, X.; Gademann; Jaun, B.; Seebach, D.; van Gunsteren, W.; Mark, A. Peptide folding: when simulation meets experiment Angew. Chem., Int. Ed. 1999, 38, 236-240
50. Garcia, A. E. Large-amplitude nonlinear motions in proteins Phys. Rev. Lett. 1992, 68, 2696-2699
51. Amadei, A.; Linssen, A. B.; Berendsen, H. J. Essential dynamics of proteins Proteins 1993, 17, 412-425
52. Hayward, S.; de Groot, B. L. Normal modes and essential dynamics Methods Mol. Biol. 2008, 443, 89-106
53. Chiappori, F.; Merelli, I.; Colombo, G.; Milanesi, L.; Morra, G. Molecular mechanism of allosteric communication in Hsp70 revealed by molecular dynamics simulations PLoS Comput. Biol. 2012, 8, e1002844
54. Gkeka, P.; Evangelidis, T.; Lazani, V.; Christoforidis, S.; Pavlaki, M.; Agianian, B.; Cournia, Z. Investigating the structure and dynamics of the PIK3CA Wild-Type and H1047R oncogenic mutant PLoS Comput. Biol. 2014, 10, 10(10):e1003895
55. Gabelli, S. B.; Huang, C. H.; Mandelker, D.; Schmidt-Kittler, O.; Vogelstein, B.; Amzel, L. M. Structural effects of oncogenic PI3Kalpha mutations Curr. Top. Microbiol. Immunol. 2010, 347, 43-53
56. Lovera, S.; Sutto, L.; Boubeva, R.; Scapozza, L.; Dolker, N.; Gervasio, F. L. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation J. Am. Chem. Soc. 2012, 134, 2496-2499
57. Bono, F.; De Smet, F.; Herbert, C.; De Bock, K.; Georgiadou, M.; Fons, P.; Tjwa, M.; Alcouffe, C.; Ny, A. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties Cancer Cell 2013, 23, 477-488
58. Sahun-Roncero, M.; Rubio-Ruiz, B.; Saladino, G.; Conejo-Garcia, A.; Espinosa, A.; Velazquez-Campoy, A.; Gervasio, F. L.; Entrena, A.; Hurtado-Guerrero, R. The mechanism of allosteric coupling in choline kinase alpha1 revealed by the action of a rationally designed inhibitor Angew. Chem., Int. Ed. Engl. 2013, 52, 4582-4586
59. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine Mol. Cell 2000, 6, 909-919
60. Panjkovich, A.; Daura, X. Exploiting protein flexibility to predict the location of allosteric sites BMC Bioinf. 2012, 13, 273
61. Segers, K.; Sperandio, O.; Sack, M.; Fischer, R.; Miteva, M.; Rosing, J.; Nicolaes, G.; Villoutreix, B., Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V. Proc. Natl. Acad. Sci. U. S. A. 104, 12697-12702.
62. Spiegel, P.; Kaiser, S.; Simon, J.; Stoddard, B. Disruption of protein-membrane binding and identification of small-molecule inhibitors of coagulation factor VIII Chem. Biol. 2004, 11, 1413-1422